Stock listing
NASDAQ:INVA Innoviva, Inc. Stock
Home listing (NASDAQ) of Innoviva, Inc.
Follow Innoviva, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:INVA
$18.41 USD +0.01 (+0.1%)
Close on Nov 20, 2026
- Day range
- $18.33 – $18.79 USDNov 20, 2026
- Volume
- 1.15M sharesNov 20, 2026
- Market cap
- $1.33B USDAt the close on Nov 20, 2026 · price × 72.25M shares outstanding
- 52-week range
- $18.23 – $25.15 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $17.58M USDMedian day 712,630 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:INVA · Home | $18.41 USD | +0.01 (+0.1%) | 1,146,551 | $18.41 | $18.79 | $18.33 | $18.40 | Close on Nov 20, 2026 |
| Frankfurt:HVE | €16.70 EUR | 0.00 (0.0%) | — | €16.70 | €16.70 | €16.70 | €16.70 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:INVA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $18.41 | +0.01 | +0.1% | $18.41 | $18.79 | $18.33 | 1,146,551 | |
| $18.40 | +0.10 | +0.5% | $18.32 | $18.54 | $18.23 | 1,188,587 | |
| $18.30 | -0.19 | -1.0% | $18.39 | $18.58 | $18.28 | 988,415 | |
| $18.49 | -0.54 | -2.8% | $19.08 | $19.24 | $18.41 | 814,143 | |
| $19.03 | +0.06 | +0.3% | $19.11 | $19.23 | $18.95 | 560,889 | |
| $18.97 | +0.11 | +0.6% | $18.99 | $19.24 | $18.86 | 563,479 | |
| $18.86 | -0.22 | -1.2% | $18.97 | $19.03 | $18.66 | 649,315 | |
| $19.08 | +0.08 | +0.4% | $20.10 | $20.10 | $18.80 | 786,108 | |
| $19.00 | -0.10 | -0.5% | $19.19 | $20.00 | $18.73 | 1,662,134 | |
| $19.10 | -0.14 | -0.7% | $19.54 | $19.87 | $19.02 | 1,654,267 | |
| $19.24 | -2.02 | -9.5% | $20.59 | $20.87 | $19.19 | 2,649,666 | |
| $21.26 | +0.33 | +1.6% | $21.28 | $21.52 | $21.03 | 922,344 | |
| $20.93 | -0.09 | -0.4% | $21.07 | $21.39 | $20.90 | 712,630 | |
| $21.02 | -0.20 | -0.9% | $21.62 | $21.62 | $20.89 | 1,120,571 | |
| $21.22 | -0.09 | -0.4% | $21.48 | $21.60 | $21.13 | 623,266 | |
| $21.31 | +0.19 | +0.9% | $21.41 | $21.52 | $21.12 | 626,925 | |
| $21.12 | +0.18 | +0.9% | $20.85 | $21.15 | $20.74 | 585,271 | |
| $20.94 | -0.11 | -0.5% | $20.97 | $21.06 | $20.75 | 584,406 | |
| $21.05 | +0.39 | +1.9% | $20.77 | $21.22 | $20.77 | 569,075 | |
| $20.66 | -0.40 | -1.9% | $20.88 | $20.94 | $20.51 | 978,553 | |
| $21.06 | +0.15 | +0.7% | $21.05 | $21.27 | $20.92 | 452,078 | |
| $20.91 | -0.37 | -1.7% | $21.20 | $21.36 | $20.89 | 442,222 | |
| $21.28 | +0.20 | +0.9% | $21.31 | $21.49 | $21.12 | 507,563 | |
| $21.08 | +0.30 | +1.4% | $20.68 | $21.15 | $20.68 | 590,514 | |
| $20.78 | -0.08 | -0.4% | $20.97 | $20.97 | $20.56 | 550,500 | |
| $20.86 | -0.11 | -0.5% | $21.33 | $21.76 | $20.83 | 673,000 | |
| $20.97 | +0.23 | +1.1% | $20.79 | $21.18 | $20.73 | 673,500 | |
| $20.74 | -0.71 | -3.3% | $21.55 | $21.55 | $20.71 | 811,600 | |
| $21.45 | +0.24 | +1.1% | $21.27 | $21.48 | $21.12 | 521,200 | |
| $21.21 | +0.34 | +1.6% | $20.80 | $21.28 | $20.78 | 507,500 | |
| $20.87 | -0.19 | -0.9% | $21.05 | $21.05 | $20.73 | 612,300 | |
| $21.06 | +0.23 | +1.1% | $20.78 | $21.10 | $20.78 | 636,300 | |
| $20.83 | +0.19 | +0.9% | $20.78 | $20.97 | $20.62 | 679,600 | |
| $20.64 | +0.14 | +0.7% | $20.53 | $20.74 | $20.45 | 993,400 | |
| $20.50 | -0.05 | -0.2% | $20.60 | $20.76 | $20.50 | 774,700 | |
| $20.55 | -0.66 | -3.1% | $21.28 | $21.28 | $20.53 | 927,100 | |
| $21.21 | +0.10 | +0.5% | $21.11 | $21.45 | $21.06 | 1,100,100 | |
| $21.11 | -0.12 | -0.6% | $21.19 | $21.19 | $20.74 | 555,800 | |
| $21.23 | +0.49 | +2.4% | $20.74 | $21.39 | $20.59 | 854,600 | |
| $20.74 | +0.08 | +0.4% | $20.70 | $20.78 | $20.35 | 623,400 | |
| $20.66 | +0.42 | +2.1% | $20.28 | $20.79 | $20.28 | 1,368,100 | |
| $20.24 | -0.74 | -3.5% | $21.11 | $21.36 | $20.23 | 4,031,100 | |
| $20.98 | -0.06 | -0.3% | $21.17 | $21.39 | $20.96 | 931,600 | |
| $21.04 | -0.10 | -0.5% | $21.10 | $21.27 | $21.00 | 688,500 | |
| $21.14 | +0.09 | +0.4% | $20.93 | $21.18 | $20.85 | 1,437,000 | |
| $21.05 | -0.15 | -0.7% | $21.22 | $21.42 | $21.00 | 1,251,900 | |
| $21.20 | +0.36 | +1.7% | $20.86 | $21.24 | $20.86 | 715,400 | |
| $20.84 | -0.06 | -0.3% | $20.86 | $20.88 | $20.50 | 1,102,000 | |
| $20.90 | +0.24 | +1.2% | $20.93 | $21.11 | $20.69 | 885,400 | |
| $20.66 | +0.04 | +0.2% | $20.84 | $20.88 | $20.45 | 727,300 | |
| $20.62 | -0.51 | -2.4% | $21.16 | $21.24 | $20.58 | 836,400 | |
| $21.13 | -0.21 | -1.0% | $21.16 | $21.41 | $20.77 | 847,400 | |
| $21.34 | +0.01 | 0.0% | $21.06 | $21.51 | $20.87 | 782,800 | |
| $21.33 | -0.02 | -0.1% | $21.20 | $21.36 | $21.09 | 563,500 | |
| $21.35 | 0.00 | 0.0% | $21.48 | $21.48 | $21.04 | 612,300 | |
| $21.35 | +0.27 | +1.3% | $21.27 | $21.48 | $21.22 | 600,600 | |
| $21.08 | +0.31 | +1.5% | $20.97 | $21.18 | $20.94 | 798,700 | |
| $20.77 | -0.20 | -1.0% | $20.97 | $21.05 | $20.68 | 877,300 | |
| $20.97 | +0.01 | 0.0% | $20.96 | $21.07 | $20.80 | 527,000 | |
| $20.96 | -0.28 | -1.3% | $20.99 | $21.10 | $20.86 | 488,100 | |
| $21.24 | +0.07 | +0.3% | $21.15 | $21.33 | $20.84 | 693,000 | |
| $21.17 | +0.14 | +0.7% | $21.10 | $21.24 | $20.93 | 412,689 | |
| $21.03 | -0.04 | -0.2% | $21.07 | $21.10 | $20.89 | 510,303 | |
| $21.07 | +0.07 | +0.3% | $21.01 | $21.23 | $20.90 | 499,400 | |
| $21.00 | -0.48 | -2.2% | $21.34 | $21.41 | $20.87 | 796,500 |
Splits
1 split · NASDAQ:INVA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 103-for-83 | Split |
- Ticker
- NASDAQ:INVA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 30 slides
Latest news
Innoviva Reports Third Quarter 2026 Financial Results; Highlights Recent Company Progress
Nov 4, 2026
Closed $19.24 (-9.5%) on Nov 5, 2026
Innoviva Specialty Therapeutics to Present Data Across Infectious Disease Portfolio at IDWeek 2026
Oct 19, 2026
Closed $21.08 (+1.4%) on Oct 19, 2026
Innoviva Specialty Therapeutics' Antimicrobial Therapies, XACDURO(R), ZEVTERA(R) and NUZOLVENCE(R) Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Aug 12, 2026
Closed $20.81 (+0.3%) on Aug 12, 2026
Innoviva Specialty Therapeutics’ Antimicrobial Therapies, XACDURO®, ZEVTERA® and NUZOLVENCE® Designated Finalists for the 2026 Prix Galien USA Best Pharmaceutical Product Award
Aug 11, 2026
Closed $20.81 (+0.3%) on Aug 12, 2026
Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress
Aug 5, 2026
Closed $21.11 (+2.9%) on Aug 6, 2026
Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets
Jun 16, 2026
Closed $22.61 (+0.8%) on Jun 16, 2026
Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress
May 6, 2026
Closed $22.80 (+1.2%) on May 7, 2026
Innoviva Specialty Therapeutics Earns Strong Performance Rating in Access to Medicine Foundation’s 2026 Antimicrobial Resistance Benchmark Report
Mar 10, 2026
Closed $22.41 (+0.4%) on Mar 10, 2026
Innoviva Reports Fourth Quarter and Full Year 2025 Financial Results; Highlights Recent Company Progress
Feb 25, 2026
Closed $24.24 (+3.5%) on Feb 25, 2026
Innoviva to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Feb 19, 2026
Closed $23.64 (-0.1%) on Feb 19, 2026
Innoviva, Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 14 in the last 12 months · 90 in all · newest Nov 4, 2026 · oldest 2019
- Decks
- 17 decks · latest August 2026
Where Innoviva, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:INVA · Home listing · This page | NASDAQ | United States | USD |
| gettex:HVE | gettex | Germany | EUR |
| LS Exchange:A2AC9U | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2AC9U | Lang & Schwarz | Germany | EUR |
| Frankfurt:HVE | Frankfurt | Germany | EUR |
| BOATS:INVA | BOATS | United States | USD |
| Tradegate:HVE | Tradegate | Germany | EUR |
| Munich:HVE | Munich | Germany | EUR |
| BX Swiss:HVE | BX Swiss | Switzerland | CHF |
| Dusseldorf:HVE | Dusseldorf | Germany | EUR |
| Stuttgart:HVE | Stuttgart | Germany | EUR |
Valuation
P/E 6.9× against a median of 40.6×: the lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $998.8M USD
- P/E
- 6.9×
- EV/sales
- 2.3×
- EV/EBITDA
- 4.7×
- Price/book
- 1.2×
- Gross margin
- 74.5%
- Operating margin
- 38.8%
- Net margin
- 44.1%
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 0.29
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Innoviva, Inc. · NASDAQ:INVA | US$1.33B | US$998.8M | 6.9× | 2.3× | 4.7× | 1.2× | 44.1% | 0.2× | 0.29 |
| Yantai Dongcheng Biochemicals Co., Ltd. Class A · SZSE:002675 | US$1.47B | US$1.41B | 46.5× | 3.6× | n/a | 2.2× | 8.0% | 0.1× | n/a |
| Fujian Haixi Pharmaceuticals Co., Ltd. Class H · HKEX:2637 | US$1.45B | US$1.27B | 54.5× | 14.5× | 41.2× | 5.8× | 30.4% | 0.0× | n/a |
| Marksans Pharma Limited · NSE:MARKSANS | US$1.42B | US$1.35B | 23.6× | 3.7× | 16.0× | 4.0× | 16.5% | 0.1× | n/a |
| Zhejiang Jingxin Pharmaceutical Co., Ltd. Class A · SZSE:002020 | US$1.41B | US$1.23B | 13.2× | 2.0× | n/a | 1.6× | 17.5% | 0.0× | n/a |
| Chengdu Olymvax Biopharmaceuticals Inc. Class A · SSE:688319 | US$1.37B | US$1.40B | n/a | 11.7× | n/a | 10.2× | −4.0% | 0.4× | n/a |
| Celltrion Pharm Inc. · KRX:068760 | US$1.34B | US$1.24B | 42.0× | 2.9× | 19.6× | 4.0× | 7.4% | 0.0× | n/a |
| Tianjin Chase Sun Pharmaceutical Co., Ltd. Class A · SZSE:300026 | US$1.31B | US$1.07B | n/a | n/a | n/a | 1.0× | n/a | 0.0× | n/a |
| Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A · SZSE:002099 | US$1.30B | US$1.18B | n/a | 3.9× | n/a | 1.9× | −11.6% | 0.0× | n/a |
| Concord Biotech Ltd. · NSE:CONCORDBIO | US$1.24B | US$1.19B | 40.6× | 9.4× | 27.3× | 5.5× | 24.1% | 0.0× | n/a |
| Zhejiang Xianju Pharmaceutical Co., Ltd. Class A · SZSE:002332 | US$1.24B | US$1.08B | 17.7× | 1.9× | n/a | 1.4× | 12.0% | 0.0× | n/a |
| Median of the others | US$1.35B | US$1.24B | 40.6× | 3.7× | 23.4× | 3.1× | 12.0% | 0.0× |
Forecasts
4 strong buy · 1 strong sell · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.80 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.86 · 5 analysts
- Revenue, year to Dec 2026
- 434.5M · 4 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Pavel Raifeld | Chief Executive Officer |
| David Patti | Corporate Communications |
| Eleanor Barisser | Investor Relations Internal |
| Irwin Tendler | Head of Investor Relations |
| David Altarac | Chief Medical Officer, IST |
| Marianne Zhen | Chief Accounting Officer |
Board
| Director | Role |
|---|---|
| Jules Haimovitz | Chairman of the Board |
| Josephine Linden | Board Member |
| Sarah J. Schlesinger | Board Member |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · After close | −9.5% |
| Q2 2026 | Aug 5, 2026 · After close | +2.9% |
| Q1 2026 | May 6, 2026 · After close | +1.2% |
| Q4 2025 | Mar 4, 2026 | −0.5% |
| Q3 2025 | Nov 5, 2025 · After close | +12.9% |
| Q2 2025 | Aug 6, 2025 · After close | +1.1% |
| Q1 2025 | May 6, 2025 · Before open | −0.2% |
| Q4 2024 | Feb 26, 2025 · After close | −2.0% |
| Q3 2024 | Nov 6, 2024 · After close | +0.4% |
| Q2 2024 | Jul 31, 2024 · After close | +2.4% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 8, 2024 · After close | −1.7% |
| Q4 2023 | Feb 29, 2024 · After close | −0.3% |
| Q3 2023 | Nov 1, 2023 · After close | +6.9% |
| Q2 2023 | Aug 2, 2023 · After close | 0.0% |
| Q1 2023 | May 9, 2023 · After close | +5.5% |
| Q4 2022 | Feb 28, 2023 · After close | −5.8% |
| Q3 2022 | Nov 9, 2022 · After close | +6.1% |
| Q2 2022 | Jul 27, 2022 · After close | −3.0% |
| Q1 2022 | Apr 27, 2022 · After close | +3.1% |
| Q4 2021 | Feb 9, 2022 · After close | +13.7% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (August 2026) | Investor deck | 30 slides | August 2026 |
| Investor Presentation (May 2024) | Investor deck | 28 slides | May 13, 2024 |
| Technical Presentation (November 2023) | Technical | 7 slides | Nov 6, 2023 |
| Investor Presentation (May 2023) | Investor deck | 22 slides | May 24, 2023 |
| Investor Presentation (September 2022) | Investor deck | 21 slides | Sep 14, 2022 |
| Investor Presentation (April 2022) | Investor deck | 22 slides | Apr 7, 2022 |
| Investor Presentation (December 2021) | Investor deck | 17 slides | Dec 13, 2021 |
| Proxy Contest (April 2017) | Proxy contest | 12 slides | Apr 18, 2017 |
| Proxy Contest (April 2017) | Proxy contest | 20 slides | Apr 12, 2017 |
| Proxy Contest (April 2017) | Proxy contest | 4 slides | Apr 3, 2017 |
All 17 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Proxy Contest (April 2017) | Proxy contest | 28 slides | Apr 3, 2017 |
| Proxy Contest (March 2017) | Proxy contest | 66 slides | Mar 30, 2017 |
| Proxy Contest (March 2017) | Proxy contest | 32 slides | Mar 28, 2017 |
| Proxy Contest (March 2017) | Proxy contest | 19 slides | Mar 27, 2017 |
| Proxy Contest (March 2017) | Proxy contest | 24 slides | Mar 23, 2017 |
| Proxy Contest (March 2017) | Proxy contest | 28 slides | Mar 7, 2017 |
| Investor Presentation (March 2016) | Investor deck | 18 slides | Mar 8, 2016 |
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 411.3M | 358.7M | 310.5M | 331.3M | 391.9M | 336.8M | 261.0M | 261.0M | 217.2M | 133.6M |
| Cost of revenue | 117.6M | 36.6M | 42.6M | 13.8M | 13.8M | 1.79M | 0 | 1.35M | 1.39M | |
| Gross profit | 307.7M | 296.2M | 246.0M | 317.5M | 391.9M | 336.8K | 261.0M | 261.0M | 217.2M | 132.2M |
| Research and development | 30.6M | 13.7M | 33.9M | 41.4M | 576.0K | 1.79M | 0 | 0 | 1.35M | 1.39M |
| Selling, general and administrative | 113.3M | 115.7M | 98.2M | 63.5M | 16.2M | 13.9M | 14.7M | 22.8M | 32.3M | 23.2M |
| Operating income | 163.7M | 166.9M | 113.9M | 207.0M | 375.1M | 321.1M | 246.4M | 238.3M | 183.6M | 109.0M |
| Depreciation and amortization | 40.2M | 39.9M | 35.7M | 19.5M | 13.8M | 13.8M | 13.9M | 13.9M | 14.0M | 14.0M |
| EBITDA | 204.0M | 206.7M | 149.6M | 226.5M | 388.9M | 335.0M | 260.2M | 252.1M | 197.6M | 122.9M |
| Interest expense | 16.7M | 22.2M | 19.2M | 15.8M | 19.1M | 18.3M | 18.7M | 24.0M | 43.6M | 52.4M |
| Income before tax | 326.9M | 37.4M | 194.1M | 286.9M | 445.3M | 354.2M | 232.9M | 210.3M | 134.3M | 59.6M |
| Income tax | 55.7M | 14.0M | 14.4M | 66.7M | 76.4M | 60.4M | 41.9M | -196.1M | 4.00K | 95.0K |
| Net income | 271.2M | 23.4M | 179.7M | 213.9M | 265.9M | 224.4M | 157.3M | 395.1M | 134.1M | 59.5M |
| Earnings per share, basic | 4.02 | 0.37 | 2.75 | 3.07 | 3.24 | 2.21 | 1.55 | 3.92 | 1.25 | 0.54 |
| Earnings per share, diluted | 3.30 | 0.36 | 2.20 | 2.37 | 2.87 | 2.02 | 1.43 | 3.53 | 1.17 | 0.53 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 550.9M | 305.0M | 193.5M | 291.0M | 201.5M | 246.5M | 278.1M | 62.4M | 73.3M | 118.0M |
| Short-term investments | 15.7M | 107.5M | 0 | 403.0M | 0 | 0 | 72.7M | 52.5M | 55.7M | 32.4M |
| Receivables | 35.0M | 86.4M | 84.1M | 64.1M | 110.7M | 93.9M | 79.4M | 83.3M | 70.5M | 46.8M |
| Inventory | 39.2M | 33.7M | 40.7M | 55.9M | 0 | -93.9M | -79.4M | -83.3M | -754.0K | -46.8M |
| Current assets | 727.5M | 554.3M | 344.2M | 443.5M | 313.7M | 342.1M | 431.2M | 199.0M | 200.4M | 198.0M |
| Property, plant and equipment | 1.55M | 514.0K | 483.0K | 170.0K | 12.0K | 28.0K | 33.0K | 160.0K | 209.0K | 368.0K |
| Goodwill | 17.9M | 17.9M | 17.9M | 26.7M | 0 | 0 | 0 | |||
| Total assets | 1.64B | 1.30B | 1.24B | 1.23B | 926.4M | 999.6M | 724.8M | 548.2M | 367.3M | 379.0M |
| Accounts payable | 4.97M | 2.13M | 6.72M | 2.94M | 27.0K | 66.0K | 10.0K | 11.0K | 601.0K | 128.0K |
| Current liabilities | 49.7M | 236.1M | 38.1M | 135.0M | 5.81M | 6.11M | 5.37M | 5.70M | 34.7M | 20.0M |
| Long-term debt | 257.7M | 256.3M | 446.2M | 444.2M | 394.7M | 385.5M | 377.1M | 382.9M | 574.4M | 708.3M |
| Total debt | 257.7M | 448.3M | 446.2M | 540.4M | 394.7M | 385.5M | 377.1M | 382.9M | 574.4M | 716.1M |
| Total liabilities | 462.3M | 609.9M | 568.6M | 665.7M | 400.5M | 391.7M | 382.7M | 389.1M | 610.0M | 732.0M |
| Shareholders' equity | 1.17B | 691.2M | 675.0M | 565.8M | 414.7M | 539.9M | 313.5M | 153.6M | -242.9M | -353.0M |
| Shares outstanding | 74.6M | 62.7M | 63.3M | 69.2M | 69.6M | 101.4M | 101.3M | 101.1M | 101.3M | 101.1M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 196.9M | 188.7M | 141.1M | 201.7M | 363.8M | 313.1M | 257.5M | 223.5M | 141.7M | 61.0M |
| Capital spending | -1.13M | -270.0K | -411.0K | -67.0K | 0 | -13.0K | -12.0K | 0 | 0 | -278.0K |
| Free cash flow | 195.8M | 188.4M | 140.7M | 201.7M | 363.8M | 313.1M | 257.4M | 223.5M | 141.7M | 60.7M |
| Cash from investing | 40.5M | -63.8M | -66.8M | -56.6M | 43.7M | -314.9M | -18.0M | 3.52M | -23.2M | -4.58M |
| Cash from financing | 8.55M | -13.5M | -171.8M | -55.6M | -452.5M | -29.8M | -23.8M | -238.0M | -163.2M | -97.6M |
| Dividends paid | -96.3M | 0 | 0 | -11.0K | -80.0K | -281.0K | -960.0K | |||
| Share buybacks | -4.53M | -14.8M | -75.7M | -8.50M | -394.1M | 0 | 0 | 0 | -97.5M | -78.1M |
| Change in cash | 246.0M | 111.5M | -97.5M | 89.5M | -45.0M | -31.6M | 215.7M | -10.9M | -44.7M | -41.2M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 27, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 24, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jul 31, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 20, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 20, 2026 | Insider trade | SEC |
| 8-K · Current report | May 18, 2026 | Management or board change | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | May 13, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2026 | Results | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | May 4, 2026 | Offer document | SEC |
| 8-K · Current report | May 4, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 29, 2026 | Big-stake notice | SEC |
| 10-K/A · Annual report, amended | Mar 27, 2026 | Annual report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 27, 2026 | Big-stake notice | SEC |
| DEF 14A · Proxy statement | Mar 24, 2026 | Meeting notice | SEC |
| 8-K · Current report | Feb 25, 2026 | Results | SEC |
| 10-K · Annual report | Feb 25, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Jan 26, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 21, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 5, 2025 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Oct 8, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Sep 3, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Aug 22, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2025 | Insider trade | SEC |
| 8-K · Current report | May 21, 2025 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Apr 28, 2025 | Big-stake notice | SEC |
| ARS · Annual report to shareholders | Apr 8, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 8, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 8, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Mar 26, 2025 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Mar 24, 2025 | Annual report | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 17, 2025 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Mar 17, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Mar 7, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 6, 2025 | Insider trade | SEC |
| 10-K · Annual report | Feb 26, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 26, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 24, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 27, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 22, 2024 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| UPLOAD · Letter from the SEC | Nov 1, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Sep 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Sep 13, 2024 | Other filings | SEC |
| 4 · Change in ownership | Aug 22, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 31, 2024 | Quarterly report | SEC |
| 8-K · Current report | Jul 31, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 20, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 21, 2024 | Insider trade | SEC |
| SC 13G · Big-stake notice | May 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | May 13, 2024 | Current report | SEC |
| ARS · Annual report to shareholders | May 8, 2024 | Annual report | SEC |
| 10-Q · Quarterly report | May 8, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 8, 2024 | Results | SEC |
| SC 13D · Big-stake notice | May 8, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | May 1, 2024 | Insider trade | SEC |
| 8-K · Current report | Apr 29, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 10-K/A · Annual report, amended | Mar 22, 2024 | Annual report | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 7, 2024 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Mar 4, 2024 | Annual report | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 4, 2024 | Big-stake notice | SEC |
| 10-K · Annual report | Feb 29, 2024 | Annual report | SEC |
| 8-K · Current report | Feb 29, 2024 | Results | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 9, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 22, 2024 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 10, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 6, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 1, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 1, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 31, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 31, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 25, 2023 | Management or board change | SEC |
| 8-K · Current report | Aug 7, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 2, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 2, 2023 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 2, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 2, 2023 | Results | SEC |
| SC 13D/A · Big-stake notice, amended | Jul 11, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jul 11, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 30, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 24, 2023 | Insider trade | SEC |
| 8-K · Current report | May 24, 2023 | Current report | SEC |
| 8-K · Current report | May 23, 2023 | Meeting outcome | SEC |
| 4 · Change in ownership | May 23, 2023 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 19, 2023 | Insider trade | SEC |
| DEFA14A · Additional proxy material | May 17, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | May 15, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | May 15, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | May 15, 2023 | Big-stake notice | SEC |
| 8-K · Current report | May 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 9, 2023 | Quarterly report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 28, 2023 | Management or board change | SEC |
| ARS · Annual report to shareholders | Apr 28, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 17, 2023 | Insider trade | SEC |
| 10-K/A · Annual report, amended | Mar 20, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 14, 2023 | Insider trade | SEC |
| 8-K · Current report | Feb 28, 2023 | Results | SEC |
| 10-K · Annual report | Feb 28, 2023 | Annual report | SEC |
| 4 · Change in ownership | Feb 22, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 13, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 10, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 9, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 1, 2023 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 26, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Jan 20, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 12, 2023 | Insider trade | SEC |
| SC 13D/A · Big-stake notice, amended | Jan 10, 2023 | Big-stake notice | SEC |
| 3 · Initial statement of ownership | Jan 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Jan 4, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Nov 22, 2022 | Insider trade | SEC |
| 10-Q · Quarterly report | Nov 9, 2022 | Quarterly report | SEC |
| 8-K · Current report | Nov 9, 2022 | Results | SEC |
| 8-K/A · Current report, amended | Oct 28, 2022 | Acquisition or disposal | SEC |
| 8-K · Current report | Sep 14, 2022 | Current report | SEC |
| 3 · Initial statement of ownership | Aug 26, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 23, 2022 | Current report | SEC |
| 4 · Change in ownership | Aug 22, 2022 | Insider trade | SEC |
| 8-K · Current report | Aug 22, 2022 | Acquisition or disposal | SEC |
| SC TO-T/A | Aug 22, 2022 | Acquisition or disposal | SEC |
| SC TO-T/A | Aug 16, 2022 | Acquisition or disposal | SEC |
| 10-Q · Quarterly report | Jul 27, 2022 | Quarterly report | SEC |
This page holds 200 of 1,000 filings. Open Filings
Cap table
Built by 6ix from Innoviva, Inc.’s releases
- Common shares
- 72,245,485
- Fully diluted
- 72,245,485
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 72,245,485 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 72,245,485 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Julian Baker Other companies: Denali Therapeutics Inc. (Director · Since at least Jun 3, 2025); Replimune Group, Inc. (Director · Since at least Mar 5, 2025); Bicycle Therapeutics PLC (Director · Since at least Apr 18, 2024); Kymera Therapeutics, Inc. (Director · Since at least Mar 28, 2024); vTv Therapeutics Inc. (Director · Since at least Feb 27, 2024); Madrigal Pharmaceuticals, Inc. (Director · Since at least Jun 15, 2023); TScan Therapeutics, Inc. (Director · Since at least Jul 15, 2021); DBV Technologies SA (Director · Since at least Jan 1, 2021); Prelude Therapeutics Incorporated (Director · Since at least Mar 27, 2020); IGM Biosciences Inc (Director · Since at least Sep 17, 2019); Kodiak Sciences Inc (Director · Since at least Oct 3, 2018); Kiniksa Pharmaceuticals International, plc (Director · Since at least Feb 9, 2018); ACADIA Pharmaceuticals Inc. (Director · Since at least Jan 18, 2013); Incyte Corporation (Managing Partner, Baker Brothers Investments | Chairman, Incyte · Since at least Apr 25, 2006); Immunocore Holdings plc (Director · May 28, 2024 – May 15, 2025 · Past); Spyre Therapeutics, Inc. (Director · Feb 23, 2021 – Jun 8, 2021 · Past); Talis Biomedical Corp (Director · Nov 2, 2020 – Jun 9, 2023 · Past); Zymeworks Inc. (Director · Mar 16, 2020 – May 8, 2020 · Past); Neurogene Inc. (Director · May 8, 2017 – Dec 18, 2023 · Past); Alexion Pharmaceuticals Inc (Director · Jun 22, 2015 – May 14, 2020 · Past); Aceragen Inc. (Director · Mar 10, 2014 – Apr 1, 2019 · Past); Ardea Biosciences Inc (Director · Apr 6, 2010 – Jun 19, 2012 · Past); Seagen Inc (Director · Jun 9, 2006 – Dec 14, 2023 · Past); Genomic Health Inc (Director · Apr 25, 2006 – Oct 1, 2019 · Past); Synageva BioPharma Corp (Director · Apr 25, 2006 – Jun 22, 2015 · Past); Neurogen Corp (Director · Mar 15, 2006 – Dec 15, 2009 · Past) | Director · Apr 26, 2006 – Apr 26, 2006 · Past |
| Barbara Duncan Other companies: Halozyme Therapeutics, Inc. (Director · Since at least Feb 3, 2023); Atea Pharmaceuticals, Inc. (Director · Since at least Oct 29, 2020); Ovid Therapeutics Inc. (Director, Chair of the Audit Committee, Member of the Nominating and Corporate Governance Committee · Since at least Jun 14, 2017); Fusion Pharmaceuticals Inc (Director · Oct 30, 2020 – Jun 4, 2024 · Past); Immunomedics Inc (Director · Mar 5, 2019 – Oct 23, 2020 · Past); Jounce Therapeutics Inc (Director · Jan 26, 2017 – May 3, 2023 · Past); Adaptimmune Therapeutics PLC (Director · Jun 23, 2016 – Jul 1, 2022 · Past); Aevi Genomic Medicine LLC (Director · Jul 22, 2015 – Feb 3, 2020 · Past); Intercept Pharmaceuticals Inc (Chief Accounting Officer · Oct 10, 2012 – Oct 3, 2016 · Past) | Director · Nov 18, 2016 – Apr 20, 2017 · Past |
| William Young Other companies: Autolus Therapeutics plc (Chair of the Nominating and Governance Committee, Member of the Research & Development Committee · Since at least Mar 18, 2026); Praxis Precision Medicines, Inc. (Director · Since at least Oct 15, 2020); Annexon, Inc. (Director · Jul 23, 2020 – Jul 23, 2020 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 26, 2022 · Past); Vertex Pharmaceuticals Incorporated (Director · May 7, 2014 – Jun 1, 2020 · Past); NanoString Technologies Inc (Director · Jun 25, 2013 – May 6, 2024 · Past); BioMarin Pharmaceutical Inc. (Director · Sep 22, 2010 – Jun 10, 2015 · Past); Human Genome Sciences Inc (Director · Apr 27, 2006 – Apr 27, 2006 · Past); Biogen Inc. (Director · Jan 9, 2006 – Jan 8, 2014 · Past) | Director · Apr 26, 2006 – May 22, 2014 · Past |
| Sapna Srivastava Other companies: Alumis Inc. (Independent Board Member · Since at least Jun 27, 2024); Aura Biosciences, Inc. (Director · Since at least Oct 28, 2021); Nuvalent, Inc. (Director · Since at least Jul 28, 2021); Tourmaline Bio Inc. (Director · Since at least May 6, 2021); Social Capital Suvretta Holdings Corp II (Director · Jun 29, 2021 – Jun 29, 2021 · Past); Intellia Therapeutics, Inc. (Chief Financial & Stategy Offr · May 5, 2016 – May 5, 2016 · Past); Medavail Holdings Inc (Director · Feb 8, 2013 – Jan 12, 2015 · Past) | Director · Jan 1, 2023 – Jun 17, 2024 · Past |
| George Bickerstaff Other companies: CareDx, Inc. (Director · Since at least Jul 16, 2014); Sio Gene Therapies Inc (Director · Feb 11, 2018 – Apr 15, 2019 · Past); Inovio Pharmaceuticals, Inc. (Director · Mar 21, 2017 – Mar 21, 2018 · Past); Ariad Pharmaceuticals Inc (Director · May 4, 2016 – Feb 16, 2017 · Past); BMP Sunstone CORP (Director · Apr 28, 2008 – Apr 28, 2008 · Past); Vion Pharmaceuticals Inc (Director · Jun 28, 2006 – Dec 11, 2008 · Past) | Director · Dec 19, 2017 – Apr 25, 2022 · Past |
| James L. Tyree Other companies: Genelux Corporation (Lead Independent Director · Since at least Jan 25, 2023); Assertio Holdings, Inc. (Director · May 19, 2020 – Mar 14, 2024 · Past); Depomed Inc (Director · Oct 17, 2016 – May 8, 2018 · Past); ChemoCentryx Inc. (Director · Jun 5, 2012 – Oct 20, 2022 · Past); Abbott Laboratories (Executive Vice President · Feb 14, 2006 – Feb 27, 2009 · Past) | Director · Jun 2, 2014 – Apr 20, 2017 · Past |
| Josephine Linden Other companies: Lands' End Inc (Director · Since at least Mar 20, 2014); Trine II Acquisition Corp (Director · Nov 2, 2021 – Nov 2, 2021 · Past); Desktop Metal Inc (Director · Mar 14, 2019 – Mar 14, 2019 · Past); Sears Hometown and Outlet Stores Inc (Director · Oct 11, 2012 – Oct 23, 2019 · Past); Bally Technologies Inc (Director · Apr 1, 2011 – Nov 21, 2014 · Past) | Board Member · Since at least May 18, 2026 |
| Kostas D Odysseas Other companies: Amarin Corporation plc (Director · Since at least Feb 28, 2023); Armata Pharmaceuticals, Inc. (Director · Since at least Feb 12, 2020); Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past); Viskase Holdings, Inc. (Director · Sep 25, 2013 – Sep 25, 2013 · Past); Savara, Inc. (Director · Feb 2, 2010 – Jun 30, 2010 · Past) | Director · Dec 19, 2017 – Jun 17, 2024 · Past |
| Mathai Mammen Other companies: Parabilis Medicines, Inc. (Chairman, CEO and President · Since at least Jun 9, 2026); Johnson & Johnson (EVP, Pharm, R&D · Jan 3, 2022 – Feb 14, 2022 · Past); 10x Genomics, Inc. (Director · Sep 11, 2019 – Jun 11, 2024 · Past); Theravance Biopharma, Inc. (SVP, Research & Development · Oct 1, 2014 – Mar 15, 2016 · Past) | SVP, Research & Early Clin Dev · Jan 4, 2008 – Aug 20, 2014 · Past |
| Terrence C Kearney Other companies: AveXis Inc (Director · Feb 10, 2016 – May 15, 2018 · Past); Acceleron Pharma Inc (Director · Jul 14, 2014 – Nov 19, 2021 · Past); Vertex Pharmaceuticals Incorporated (Director · May 17, 2011 – May 1, 2024 · Past); Hospira Inc (Chief Operating Officer · May 17, 2006 – Dec 15, 2010 · Past) | Director · Oct 30, 2014 – Apr 24, 2015 · Past |
All 48 people
| Person | Seat |
|---|---|
| Eve Elizabeth Slater Other companies: Aceragen Inc. (Director · Jun 16, 2010 – Jun 8, 2015 · Past); Phase Forward Inc (Director · Feb 26, 2007 – Feb 26, 2007 · Past); Vertex Pharmaceuticals Incorporated (Director · Mar 23, 2006 – Jun 1, 2007 · Past) | Director · Apr 26, 2006 – Apr 25, 2007 · Past |
| George Whitesides Other companies: Lyra Therapeutics, Inc. (Woodford L. and Ann A. Flowers University Professor, Harvard University · Since at least Apr 30, 2020); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 27, 2021 · Past); Rohm & Haas Co (Director · Jan 9, 2006 – Apr 1, 2009 · Past) | Director · Apr 26, 2006 – May 22, 2014 · Past |
| Henrietta Fore Other companies: General Mills, Inc. (Director · Jun 24, 2014 – Sep 26, 2017 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Aug 11, 2017 · Past); Exxon Mobil Corporation (Director · Feb 29, 2012 – Dec 31, 2017 · Past) | Director · Oct 20, 2010 – May 22, 2014 · Past |
| Leonard M Blum Other companies: EyePoint, Inc. (See Remarks · May 14, 2018 – May 14, 2018 · Past); Theravance Biopharma, Inc. (Sr VP, Chief Comm. Officer · Oct 1, 2014 – Feb 20, 2016 · Past); Icos Corp (Senior VP, Sales and Marketing · Dec 29, 2005 – Jan 29, 2007 · Past) | Sr VP, Chief Comm. Officer · Jul 30, 2007 – Aug 20, 2014 · Past |
| Mark DiPaolo Other companies: OneIM Acquisition Corp. (Director · Since at least Jan 13, 2026); Amarin Corporation plc (Director · Feb 28, 2023 – Apr 18, 2025 · Past); Sarissa Capital Acquisition Corp (Senior Managing Director · Oct 20, 2020 – Oct 20, 2020 · Past) | Director · Since at least Apr 24, 2019 |
| Rick E Winningham Other companies: Theravance Biopharma, Inc. (CHIEF EXECUTIVE OFFICER, Director · Since at least May 14, 2014); Jazz Pharmaceuticals plc (Director · Since at least May 4, 2010); OncoMed Pharmaceuticals Inc (Director · Jun 24, 2015 – Jun 22, 2018 · Past) | Director · Feb 8, 2006 – Aug 15, 2014 · Past |
| Robert V Gunderson Jr Other companies: Andersen Group Inc. (Director · Since at least Dec 16, 2025); Vitae Pharmaceuticals Inc (Director · Sep 24, 2014 – Oct 24, 2016 · Past); Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 27, 2021 · Past) | Director · Apr 26, 2006 – May 22, 2014 · Past |
| Sarah J. Schlesinger Other companies: Armata Pharmaceuticals, Inc. (Director · Since at least Feb 12, 2020); The Medicines Company (Director · Feb 22, 2018 – Jan 6, 2020 · Past); Ariad Pharmaceuticals Inc (Director · Jul 15, 2013 – Feb 13, 2017 · Past) | Board Member · Since at least Feb 12, 2018 |
| Frank Pasqualone Other companies: Enveric Biosciences, Inc. (Director · Since at least Jul 13, 2022); Theravance Biopharma, Inc. (SVP, CHIEF BUSINESS OFFICER · May 14, 2014 – Nov 19, 2021 · Past) | Sr. Vice President, Operations · Jan 13, 2014 – Jan 23, 2014 · Past |
| Jeffrey David Jonker Other companies: Metacrine Inc (Director · Mar 17, 2021 – May 18, 2022 · Past); Theravance Biopharma, Inc. (Senior VP, Corp. & Bus. Dev. · May 14, 2014 – Jun 3, 2014 · Past) | Senior VP, Corp. & Bus. Dev. · Oct 14, 2013 – Oct 22, 2013 · Past |
| Michael Faerm Other companies: AtaiBeckley Inc. (Chief Financial Officer · Since at least Feb 19, 2026); Viracta Therapeutics Inc (Chief Financial Officer · May 13, 2024 – May 14, 2024 · Past) | Sr VP & Chief Business Officer · Jul 14, 2015 – Nov 20, 2017 · Past |
| Peter S Ringrose Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – Apr 30, 2019 · Past); Rigel Pharmaceuticals, Inc. (Director · May 28, 2010 – May 17, 2018 · Past) | Director · Apr 27, 2010 – May 22, 2014 · Past |
| Bradford J Shafer Other companies: Theravance Biopharma, Inc. (EVP, Gen. Counsel, Secretary · Sep 1, 2014 – Aug 20, 2021 · Past) | Sr VP, Gen. Counsel, Secretary · Feb 8, 2006 – Aug 20, 2014 · Past |
| Burton G Malkiel Other companies: Theravance Biopharma, Inc. (Director · May 14, 2014 – May 2, 2023 · Past) | Director · Jul 3, 2007 – May 22, 2014 · Past |
| David Altarac Other companies: Entasis Therapeutics Holdings Inc (Chief Medical Officer · Nov 4, 2019 – Jul 7, 2022 · Past) | Chief Medical Officer, IST · Since at least Oct 19, 2026 |
| Deborah Birx Other companies: Armata Pharmaceuticals, Inc. (Chief Executive Officer · Since at least Jul 10, 2023) | Director · Mar 9, 2021 – May 22, 2023 · Past |
| Derek A Small Other companies: Assembly Biosciences, Inc. (Director · Jul 11, 2014 – Jan 2, 2020 · Past) | Director · Since at least Apr 29, 2024 |
| Jules Haimovitz Other companies: Armata Pharmaceuticals, Inc. (Director · Since at least Apr 1, 2021) | Director · Since at least Feb 12, 2018 |
| Junning Lee Other companies: Theravance Biopharma, Inc. (Sr. VP, Technical Operations · Sep 1, 2014 – Feb 20, 2017 · Past) | Sr. VP, Technical Operations · Jan 6, 2014 – Aug 20, 2014 · Past |
| Larry G Edwards Other companies: La Jolla Pharmaceutical Co (Chief Executive Officer, Director · Dec 10, 2020 – Aug 22, 2022 · Past) | CEO of La Jolla Pharmaceutical · Aug 22, 2022 – Aug 22, 2022 · Past |
| Margaret Koziel Other companies: Axcella Health Inc (Chief Medical Officer · Dec 1, 2021 – Mar 1, 2023 · Past) | Chief Medical Officer · Jul 31, 2023 – Jul 31, 2023 · Past |
| Matthew Ronsheim Other companies: Entasis Therapeutics Holdings Inc (Chief of Pharma Sciences & MFG · Sep 9, 2020 – Jul 7, 2022 · Past) | See Remarks · Jan 1, 2024 – May 20, 2024 · Past |
| Michael Kitt Other companies: Portola Pharmaceuticals Inc (Senior VP and CMO · May 21, 2013 – May 21, 2013 · Past) | Sr. Vice President Development · Feb 8, 2006 – Jun 2, 2008 · Past |
| P Roy Vagelos Other companies: Regeneron Pharmaceuticals, Inc. (Director · Dec 31, 2005 – Apr 3, 2023 · Past) | Director · Apr 26, 2006 – Dec 23, 2009 · Past |
| Stephen Basso Other companies: Inozyme Pharma Inc (SVP Finance (PFO) · Jul 23, 2020 – Mar 24, 2021 · Past) | Chief Financial Officer · Since at least Aug 21, 2023 |
| Arthur L Campbell | Sr. VP, Technical Operations · Feb 8, 2006 – Jan 29, 2008 · Past |
| David Patti | Corporate Communications · Since at least Dec 15, 2025 |
| Eleanor Barisser | Investor Relations Internal · Since at least May 6, 2026 |
| Eric dEsparbes | SVP and CFO · Oct 9, 2014 – May 20, 2018 · Past |
| Geoffrey Hulme | Interim Principal Exec Officer · May 21, 2018 – May 20, 2020 · Past |
| Irwin Tendler | Head of Investor Relations · Since at least Aug 12, 2026 |
| Marianne Zhen | Chief Accounting Officer · Since at least Aug 3, 2018 |
| Patrick PA Humphrey | Executive VP Research · Feb 8, 2006 – Dec 10, 2007 · Past |
| Paul Pepe | Director · Jun 2, 2014 – Apr 20, 2017 · Past |
| Pavel Raifeld | Chief Executive Officer · Since at least May 20, 2020 |
| Ronn Loewenthal | Director · Apr 26, 2006 – May 2, 2006 · Past |
| Theodore J Witek Jr | Sr. VP & Chief Scientific Off. · Jul 1, 2014 – Aug 20, 2018 · Past |
| William H Waltrip | Director · Apr 26, 2016 – Apr 20, 2017 · Past |
Log in to ask 6ix AI your own questions about Innoviva, Inc.